Literature DB >> 28096158

Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.

Manjunath P Pai1, Joseph Hong2, Lynne Krop2.   

Abstract

Vancomycin area under the curve (AUC) estimates may be skewed in obese adults due to weight-dependent pharmacokinetic parameters. We demonstrate that peak and trough measurements reduce bias and improve the precision of vancomycin AUC estimates in obese adults (n = 75) and validate this in an independent cohort (n = 31). The precision and mean percent bias of Bayesian vancomycin AUC estimates are comparable between covariate-dependent (R2 = 0.774, 3.55%) and covariate-independent (R2 = 0.804, 3.28%) models when peaks and troughs are measured but not when measurements are restricted to troughs only (R2 = 0.557, 15.5%).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MRSA; obese; obesity; peak; pharmacodynamics; pharmacokinetics; population pharmacokinetics; trough; vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28096158      PMCID: PMC5365684          DOI: 10.1128/AAC.02490-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Estimating the glomerular filtration rate in obese adult patients for drug dosing.

Authors:  Manjunath P Pai
Journal:  Adv Chronic Kidney Dis       Date:  2010-09       Impact factor: 3.620

Review 3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

4.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

5.  Vancomycin dosing in morbidly obese patients.

Authors:  L A Bauer; D J Black; J S Lill
Journal:  Eur J Clin Pharmacol       Date:  1998-10       Impact factor: 2.953

6.  Estimating creatinine clearance: a meta-analysis.

Authors:  Sheila M Wilhelm; Pramodini B Kale-Pradhan
Journal:  Pharmacotherapy       Date:  2011-07       Impact factor: 4.705

7.  Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.

Authors:  Joseph Hong; Lynne C Krop; Tracy Johns; Manjunath P Pai
Journal:  Pharmacotherapy       Date:  2015-05       Impact factor: 4.705

8.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

Review 9.  Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Authors:  Manjunath P Pai; Michael Neely; Keith A Rodvold; Thomas P Lodise
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

  9 in total
  3 in total

1.  Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging.

Authors:  Manjunath P Pai; Brian A Derstine; Matt Lichty; Brian E Ross; June A Sullivan; Grace L Su; Stewart C Wang
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 2.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

3.  Why we should sample sparsely and aim for a higher target: Lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients.

Authors:  Tingjie Guo; Reinier M van Hest; Lucas M Fleuren; Luca F Roggeveen; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Johan G C van Hasselt; Paul W G Elbers
Journal:  Br J Clin Pharmacol       Date:  2020-08-17       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.